

Table S1. Patient characteristics after propensity score matching – differences between the group with and without persistent smell and taste disorders.

	Smell and taste disorders (n = 98)	No smell and taste disorders (n=980)	p-value*
Age**	49.19±14.68	28.5±13.02	0.698
Women	32 (32.65%)	353 (36.4)	0.863
Men	66 (67.35%)	637 (63.4)	
Weight **	76.58±15.64	78.19±18.04	0.372
Height **	169.13±8.38	168.87±8.63	0.401
BMI <30	76 (77.55%)	696 (70.6)	0.234
BMI ≥30	22 (22.45%)	284 (29.4)	
Number of comorbidities **	1.29±1.44	1.52±1.60	0.072
Comorbidities	56 (57.14%)	624 (63.7)	0.094
Hypertension (HT)	24 (24.49%)	276 (28.2)	0.467
Thyroid disease	17 (17.35%)	181 (18.5)	0.451
Hyperlipidemia	14 (14.29%)	170 (17.4)	0.814
Diabetes mellitus (DM)	11 (11.22%)	68 (6.9)	0.662
Coronary artery disease	3 (3.06%)	36 (3.7)	0.581
Previous myocardial infarction (MI)	1 (1.02%)	12 (1.2)	0.778
Heart failure	0 (0.00%)	13 (1.3)	0.710
Venous thromboembolism	1 (1.02%)	13 (1.3)	0.650
Asthma	7 (7.14%)	89 (9.08)	0.884
COPD	1 (1.02%)	18 (1.9)	0.756
Flu vaccinations in the previous season	3 (3.06%)	64 (6.6)	0.175
Vaccination against COVID-19 (n=532) / (n=23 for smell and taste disorders)	17 (73.91%)	369 (69.5)	0.652

BMI – Body Mass Index, HT – hypertension, DM – diabetes mellitus, MI – myocardial infarction, COPD – chronic obstructive pulmonary disease, * Chi-square test – distribution among patients with/without persistent smell and taste disorders, ** Mann–Whitney U test.

Table S2. COVID-19 course analysis in groups with and without persistent smell and taste disorders. Comparison after propensity score matching.

	Smell and taste disorders (n = 98)	No smell and taste disorders (n=980)	p-value*
Pandemic wave			
2	67 (68.37%)	617 (62.9%)	0.051
3	21 (21.43%)	293 (29.9%)	
4	10 (10.20%)	70 (7.2%)	
Course of COVID-19			
0	8 (8.16%)	78 (8.0)	0.853
1	35 (35.71%)	314 (32.0)	
2	25 (25.51%)	276 (28.2)	
3	30 (30.61%)	312 (31.8)	
Home isolation	95 (96.94%)	884 (90.2%)	0.115

Hospitalisation without pneumonia	0 (0.00%)	12 (1.2%)	0.778
Hospitalisation with pneumonia	1 (1.02%)	73 (7.4%)	0.128
Hospitalisation with ICU	0 (0.00%)	4 (0.5)	0.647
Symptoms during COVID-19			
Temperature <36.6	20 (20.41%)	142 (14.5%)	0.312
Temperature <37.5	23 (23.47%)	226 (23.1%\$)	0.899
Temperature > 37.5	46 (46.94%)	527 (53.8%)	0.413
Cough	54 (55.10%)	612 (62.5)	0.457
Dyspnoea	45 (45.92%)	442 (45.1%)	0.952
Olfactory dysfunction	10 (10.20%)	99 (10.2%)	0.953
Taste dysfunction	1 (1.02%)	55 (5.7%)	0.092
Smell and taste disorders	82 (83.67%)	473 (48.3%)	<0.001
Significant fatigue	69 (70.41%)	738 (75.4%)	0.503
Chest pain	45 (45.92%)	452 (46.2%)	0.516
Back muscle pain	50 (51.02%)	526 (53.7%)	0.713
Leg muscle pain	48 (48.98%)	411 (42.0%)	0.051
Headache	59 (60.20%)	611 (62.3%)	0.470
Arthralgia	50 (51.02%)	404 (41.2%)	0.021
Diarrhoea	21 (21.43%)	187 (19.1%)	0.540
Vomiting	4 (4.08%)	72 (7.4%)	0.909
Chills	36 (36.73%)	378 (38.6%)	0.932
Labile blood pressure values	16 (16.33%)	134 (13.7%)	0.850
Hearing dysfunction	14 (14.29%)	95 (9.7%)	0.219
Duration of symptoms (number of days)**	10.43±5.49	10.64±5.64	0.642
Number of symptoms**	8.87±3.65	8.29±3.63	0.021

ICU – intensive care unit, *Chi-square test – distribution among people with/without persistent smell and taste disorders. ** the Mann–Whitney U test.